We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
About our treatment-resistant depression clinical development programme
Sometimes depression doesn't get better, even with treatment. ‘Treatment-resistant depression’ (TRD) is a term used when people with depression do not respond adequately to at least two different antidepressant medications.
Depression is the leading cause of disability and ill health worldwide. Up to two-thirds of people with depression are not helped by the first antidepressant medication they try. Up to a third of people with depression are failed by multiple attempts at treatment.
Hear what it’s like to live with treatment-resistant depression
We have received FDA Breakthrough Therapy designation and Innovative Licensing and Access Pathway designation for our COMP360 psilocybin for TRD. In late 2021, we completed a randomised, controlled, double-blind phase 2b study of COMP360 psilocybin therapy in 233 patients with TRD in 22 sites across Europe and North America.
We are working as quickly as we can to develop COMP360 psilocybin therapy for people suffering with TRD. We will update this page with details about the sites that will be involved in our phase 3 trial once they have been approved.